Hantech Bio-Technology（1294）株式概要Hantech Bio-Technology Co, Ltd.は台湾で健康補助食品を製造・販売している。 詳細1294 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金3/6報酬株価収益率（ 13.7 x） TW市場（ 20.7 x）を下回っています。リスク分析意味のある時価総額がありません ( NT$2B )すべてのリスクチェックを見る1294 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,236 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,236 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$56.4034.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0832m2016201920222025202620282031Revenue NT$831.9mEarnings NT$149.6mAdvancedSet Fair ValueView all narrativesHantech Bio-Technology Co., Ltd. 競合他社Luo Lih-Fen HoldingSymbol: TWSE:6666Market cap: NT$2.0bG&E Herbal BiotechnologySymbol: TPEX:4911Market cap: NT$1.8bJia Jie BiomedicalSymbol: TPEX:4109Market cap: NT$1.3bMaywufaSymbol: TWSE:1731Market cap: NT$2.7b価格と性能株価の高値、安値、推移の概要Hantech Bio-Technology過去の株価現在の株価NT$56.4052週高値NT$79.4252週安値NT$53.30ベータ-0.251ヶ月の変化-7.54%3ヶ月変化-13.45%1年変化-13.01%3年間の変化7.26%5年間の変化n/aIPOからの変化164.57%最新ニュースValuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.お知らせ • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county TaiwanBoard Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.お知らせ • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county TaiwanNew Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).株主還元1294TW Personal ProductsTW 市場7D0.5%-0.6%4.3%1Y-13.0%-31.4%81.1%株主還元を見る業界別リターン: 1294過去 1 年間で-31.4 % の収益を上げたTW Personal Products業界を上回りました。リターン対市場: 1294は、過去 1 年間で81.1 % のリターンを上げたTW市場を下回りました。価格変動Is 1294's price volatile compared to industry and market?1294 volatility1294 Average Weekly Movement3.9%Personal Products Industry Average Movement4.2%Market Average Movement6.6%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.7%安定した株価: 1294 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1294の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007n/an/awww.htbios.comHantech Bio-Technology Co., Ltd.は台湾で健康補助食品を製造・販売している。OEMやODMのパートナーシップのもと、ジェル状、液体状、粉末状の栄養補助食品を提供している。同社は、長方形、曲線、Z、円形、ワインボトル、スタンディングパウチなど、様々なパッケージでサプリメントを提供している。ハンテック・バイオ・テクノロジー社は2007年に設立され、本社は台湾の元林市にある。もっと見るHantech Bio-Technology Co., Ltd. 基礎のまとめHantech Bio-Technology の収益と売上を時価総額と比較するとどうか。1294 基礎統計学時価総額NT$2.04b収益（TTM）NT$149.62m売上高(TTM)NT$831.92m13.7xPER（株価収益率2.5xP/Sレシオ1294 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1294 損益計算書（TTM）収益NT$831.92m売上原価NT$524.37m売上総利益NT$307.55mその他の費用NT$157.93m収益NT$149.62m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）4.12グロス・マージン36.97%純利益率17.98%有利子負債／自己資本比率9.3%1294 の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.4%現在の配当利回り61%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 16:30終値2026/08/05 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hantech Bio-Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Hsiu Chi LinMasterlink Securities Investment AdvisoryKyeongkeun KangNH Investment & Securities Co., Ltd.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.
お知らせ • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county Taiwan
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).
Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).
Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.
Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.
お知らせ • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county Taiwan
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).
New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.
Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.
New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).
New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).
New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).
New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).
